Polycystic Liver Disease
16
2
3
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.3%
1 terminated out of 16 trials
88.9%
+2.4% vs benchmark
0%
0 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (16)
Polycystic Liver Disease Registry (UK)
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
Pasireotide LAR in Severe Polycystic Liver Disease
Automatic Segmentation of Polycystic Liver
Everolimus and LongActing Octreotide Trial in Polycystic Livers
Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
Polycystic Liver Disease in Kidney Transplant
Octreotide in Severe Polycystic Liver Disease
Lanreotide as Treatment of Polycystic Livers
Open-Label Extension of LOCKCYST Trial